JNJvsLLY
Johnson & Johnson vs Eli Lilly and Co. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
Johnson & Johnson
$234.18
+16.15%
Eli Lilly and Co
$927.03
-6.70%
60-day price, rebased to 100
Round-by-round
Valuation upside
-49.50% vs -92.70% to DCF fair value
Balance-sheet strength
Altman Z 5.48 vs 15.74
Fundamental quality
Piotroski 4.00 vs 6.00 (of 9)
Growth + margins
Rule-of-40 -5.70 vs -9.10
60-day momentum
+7.18% vs -12.77% price return
Market-cap liquidity
$585.7B vs $884.0B
Verdict
Across 6 categories, the two names are evenly matched — 3 wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy on JNJ or LLY
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.